Cresco Labs CEO says cannabis rescheduling to Schedule III validates medical use

Colgate-Palmolive Company

Colgate-Palmolive Company

CL

0.00
  • Cresco Labs CEO Charlie Bachtell welcomed Justice Department final rule rescheduling medical cannabis to Schedule III from Schedule I under Controlled Substances Act.
  • Bachtell said shift aligns federal policy with scientific evidence, marking first federal classification of cannabis as medicine.
  • He said change could expand research, improve clinical data, support more informed care, broaden patient access nationwide.
  • Bachtell said move could treat cannabis like other medicines, describing it as start of a new healthcare era for patients.
  • He commended President Trump administration for adopting what he called a commonsense approach to cannabis regulation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cresco Labs Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604231324BIZWIRE_USPR_____20260423_BW797861) on April 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.